The significance of the result lies in the changing philosophy of drug design. For decades, approved medicines leaned heavily on flat, aromatic ring systems that were easy to synthesize but often suffered from poor solubility, metabolic liabilities and crowded intellectual property space. The influential concept of escape from flatland, articulated by Frank Lovering and colleagues in 2009, linked greater molecular saturation, quantified by the fraction of sp3 carbons, with improved clinical success rates. Since then, the fraction of sp3 character has become a recognized parameter of drug-likeness, and chemists have scrambled to invent efficient routes to saturated, three-dimensionally rich frameworks that can stand in for the aromatic and heteroaromatic rings of legacy drugs.

Piperidine is perhaps the single most important saturated ring in medicinal chemistry, appearing in a strikingly large share of FDA-approved pharmaceuticals, from analgesics to antipsychotics. But its ubiquity is precisely the problem: when a piperidine appears in a candidate drug, it offers limited novelty, and its geometry is a simple chair. Bioisosteres, fragments that mimic the size, shape and electronics of an established motif while changing its underlying scaffold, offer a route to analogues with altered physicochemical properties, modified metabolic profiles and defensible patent positions. Spirocyclic azetidines such as 2-azaspiro[3.3]heptane fuse a four-membered nitrogen-containing ring directly onto a cyclobutane at a single shared atom, producing a rigid, globular structure that projects substituents in three dimensions in ways piperidine cannot.

Until now, that promise has outrun practical access. Chemists led by Pavel Mykhailiuk and others had highlighted 1- and 2-azaspiro[3.3]heptanes as overlooked motifs for drug discovery and demonstrated their value as piperidine mimics, but the known routes were largely stoichiometric, lengthy and achiral, delivering racemic products or requiring resolution. No catalytic method for the asymmetric construction of 2-azaspiro[3.3]heptanes had been reported. Because most drug targets are chiral proteins, the two mirror-image forms of such a scaffold can behave very differently in the body, so a route that delivers a single enantiomer directly from simple precursors represents exactly the kind of enabling methodology that medicinal chemistry teams need.

The Chongqing team’s solution hinges on enantioselective reductive amination, a transformation in which a carbonyl compound and an amine combine to form an imine or iminium intermediate that is then reduced to a new carbon-nitrogen bond with catalyst-controlled chirality. Reductive amination is a mainstay of industrial chemistry, and catalytic versions using molecular hydrogen or metal hydrides are well developed; asymmetric variants have likewise been explored with transition metals and, pioneered by the groups of David MacMillan, Tsutomu Akiyama and Benjamin List, with chiral organic acids and hydride donors such as benzothiazolines. What the Dai group recognized was that this organocatalytic logic could be transplanted onto spirocyclic ketone substrates whose reduction would forge the stereogenic center at the heart of the 2-azaspiro[3.3]heptane framework in a single, convergent step.

In practice, a chiral phosphoric acid activates both the iminium formed from the spirocyclic ketone precursor and the hydride donor through simultaneous hydrogen bonding and ion pairing, creating a tightly organized chiral pocket in which hydride delivery to one face of the iminium is strongly preferred over delivery to the other. The result is a product enantiomer formed in high yield with excellent enantiomeric excess. Because the substrates are prepared from commercially available materials, the entire sequence offers a concise and scalable entry into scaffold variants that previously demanded multistep campaigns, and the reaction tolerates a broad range of amine partners and substitution patterns, as documented across the extensive substrate scope mapped in the study.

The authors did not stop at proving the reaction works. Mechanistic experiments and density functional theory calculations were used to map the possible reaction pathways and to rationalize the origin of the enantioselectivity, identifying the favored transition-state organization inside the catalyst pocket. Wavefunction-based analyses of the noncovalent interactions between catalyst and substrate provided a visual, quantified picture of the attractive forces that lock the iminium into the productive orientation. This combination of experiment and computation matters beyond the immediate reaction: it turns a useful empirical discovery into a transferable design principle that other groups can apply to related spirocyclic imines and to neighboring organocatalytic reductions.

The synthetic payoff is demonstrated in a series of onward transformations that convert the enantioenriched spirocycles into chiral building blocks suitable for the concise assembly of drug-like molecules. Most strikingly, the team applied the chemistry to an IRE1α inhibitor, a class of compounds that targets the unfolded protein response, a signaling pathway implicated in cancer survival. By swapping the piperidine motif of the inhibitor for the chiral 2-azaspiro[3.3]heptane bioisostere, the researchers obtained analogues exhibiting enhanced inhibitory activity together with improved absorption and metabolic properties. That a scaffold chosen for its three-dimensional shape also improves potency and pharmacokinetics in a real pharmacological context is precisely the outcome the bioisostere concept hopes for, and it is rarely demonstrated so directly.

The broader implications extend across the drug discovery pipeline. A robust catalytic route to chiral piperidine bioisosteres gives medicinal chemists a new, freely substitutable module for lead optimization: whenever a flat or metabolically fragile piperidine underperforms, this spirocycle can now be considered not just in principle but in practice, on scale, in either enantiomer. The work also strengthens the case for spirocyclic azetidines generally, a fragment class whose angular geometry and high fraction of sp3 character continue to attract attention in fragment-based screening and patent-focused scaffold hopping. As computational tools for predicting bioisosteric compatibility improve, methods such as this one supply the physical compounds those tools demand.

There are, of course, familiar caveats. The chemistry relies on organocatalytic transfer conditions whose substrate tolerance, while broad, will need to be stretched further for highly functionalized late-stage intermediates, and the cost and availability of chiral phosphoric acid catalysts on process scale will shape industrial uptake. Yet the trajectory of the field suggests these are engineering problems rather than conceptual barriers. What the Chongqing team has established is a first: the catalytic, asymmetric synthesis of 2-azaspiro[3.3]heptanes from simple starting materials, executed with the yields and selectivities that industrial adoption requires, validated computationally, and proven in a bona fide drug-discovery application. It is a vivid illustration of how modern organic synthesis, guided by the escape-from-flatland imperative, is quietly reshaping the chemical inventory from which the next generation of medicines will be built.

Beyond the headline result, the study offers a useful lesson in how stereochemical information can be installed at the very core of a ring system rather than at a peripheral substituent. In many asymmetric routes to saturated heterocycles, the stereocenter arises during bond formation at the scaffold’s edge, leaving the ring framework itself achiral. Here, the reductive amination step creates the stereogenic center at the spiro junction region, meaning the entire three-dimensional architecture inherits a defined handedness from the very operation that closes the molecule. That design choice is what allows the two enantiomers of the bioisostere to be accessed selectively, simply by switching the catalyst enantiomer.

The choice of a chiral phosphoric acid as catalyst also carries practical advantages worth noting. These organocatalysts are metal-free, operate under mild conditions, and avoid the residual heavy-metal concerns that can complicate the route from discovery chemistry toward good-manufacturing-practice production of clinical candidates. For pharmaceutical applications, where trace metal specifications are increasingly stringent, an organocatalytic entry to a chiral building block is an attractive feature in its own right, complementing the reaction’s use of commercially available starting materials.

The crystallographic work underpinning the study deserves mention as well. Definitive structural assignments for key products were secured through X-ray diffraction analyses, with the corresponding coordinates deposited in the Cambridge Structural Database, providing the community with verified three-dimensional reference structures of the scaffold. For a motif whose value depends precisely on its geometry, having experimentally determined structures available supports the computational modeling that medicinal chemists will inevitably perform when comparing the spirocycle against piperidine analogues.

Finally, the IRE1α application illustrates a point about how bioisosteric replacements should be evaluated. Rather than asserting similarity on purely geometric grounds, the authors measured what actually matters: target potency, absorption, and metabolic stability. The observation that the spirocyclic analogue outperformed its piperidine parent on these pharmacological endpoints provides empirical support for the escape-from-flatland hypothesis at the level of a specific drug target, evidence that will likely encourage other optimization campaigns to test saturated spirocyclic replacements earlier in the design cycle.

Subject of Research: Catalytic asymmetric synthesis of chiral 2-azaspiro[3.3]heptanes as piperidine bioisosteres for medicinal chemistry

Article Title: Enantioselective synthesis of chiral 2-azaspiro[3.3]heptanes and their application as piperidine bioisosteres

Article References: Qiu, Y.-K., Tang, Y.-P., Zhang, C.-G., Huang, Q., Li, J., Chen, L., Wang, Z., & Dai, L. (2026). Enantioselective synthesis of chiral 2-azaspiro[3.3]heptanes and their application as piperidine bioisosteres. Nature Synthesis. https://doi.org/10.1038/s44160-026-01147-9

Image Credits: AI Generated

DOI: 10.1038/s44160-026-01147-9

Keywords: 2-azaspiro[3.3]heptane, piperidine bioisostere, enantioselective synthesis, reductive amination, chiral phosphoric acid, asymmetric catalysis, organocatalysis, medicinal chemistry, spirocyclic azetidines, drug discovery, escape from flatland, IRE1α inhibitor

The study, led by Professors Cheng-Yong Su and Peng Hu, demonstrates the intermolecular asymmetric dearomative photocycloaddition of (benzo)furans with photoactive alkenes. The work, published in the Chinese Journal of Catalysis, uses enzyme-mimetic Δ/Λ-MOC-16 catalysts to organize the reaction inside a confined molecular environment. The resulting process converts relatively flat aromatic starting materials into structurally intricate fused polycyclic products, reaching yields of up to 98 percent, diastereomeric ratios above 20:1, and enantiomeric excesses as high as 99 percent.

Dearomatization is a valuable strategy in synthetic chemistry because aromatic rings are stable, planar, and abundant, while many biologically active molecules contain saturated or partially saturated three-dimensional ring systems. Transforming an aromatic structure into a non-aromatic one can therefore rapidly increase molecular complexity. Photocycloaddition reactions are particularly attractive for this purpose because visible light can activate substrates under relatively mild conditions and generate multiple chemical bonds in a single step.

Most previous photocatalytic dearomatization reactions have relied on excited aromatic compounds reacting with ordinary, ground-state alkenes. In the new approach, the roles are reversed. The (benzo)furan remains in its ground state and acts as the non-photoactive aromatic partner, while the alkene absorbs energy and enters an excited state. This arrangement is chemically demanding because excited alkenes are highly reactive and often short-lived, making it difficult to guide them toward a single reaction pathway or control the formation of one enantiomer over the other.

The researchers addressed this challenge by placing both reaction partners inside a chiral metal–organic cage. These cages are assembled from metal centers and organic ligands to produce hollow molecular architectures with internal cavities. The Δ and Λ forms of MOC-16 create mirror-image confined environments, analogous in some respects to the active sites of enzymes. Within the cage, the substrates are not free to collide randomly in solution. Instead, they can be selectively encapsulated, positioned near one another, and held in an orientation favorable for the desired photocycloaddition.

A combination of mechanistic experiments supported this interpretation. Stern–Volmer quenching studies indicated how the catalyst and substrates interact during the photochemical process, while ultraviolet–visible absorption measurements helped clarify the participation of the photoactive alkene. Control experiments confirmed that the cage was not simply an inert container but played an active catalytic role. Proton nuclear magnetic resonance titration and solubilization studies further showed that the catalyst can dynamically bind the substrates, increasing their effective local concentration and influencing their relative arrangement.

This confined environment is crucial because photocatalytic reactions often suffer from competing pathways caused by the rapid diffusion and high reactivity of excited molecules. The cage restricts the movement and geometry of the excited alkene, while its chiral interior differentiates between the two possible facial approaches to the furan substrate. As a result, the catalyst can simultaneously influence regioselectivity, diastereoselectivity, and enantioselectivity. In practical terms, it helps determine where the new bonds form, how the newly created rings are connected in space, and which mirror-image product predominates.

The reaction also displayed broad substrate tolerance. Cinnamate-derived alkenes and a range of (benzo)furans bearing electronically different substituents were compatible with the method. Substituents at varied positions and groups imposing different degrees of steric hindrance could be accommodated without destroying the selectivity of the transformation. This flexibility is important for medicinal chemistry and materials research, where the ability to modify molecular structures without redesigning an entire synthetic route can greatly accelerate the discovery of useful compounds.

The value of the products extends beyond the initial photocycloaddition. The researchers successfully subjected the cycloadducts to several subsequent transformations, including epimerization, ring-opening reactions, and Suzuki–Miyaura cross-coupling. These reactions demonstrate that the newly generated polycyclic frameworks can serve as versatile intermediates rather than chemically static end products. By combining light activation, asymmetric catalysis, and cage-based molecular recognition, the study establishes a new reaction platform for building complex chiral molecules from comparatively simple starting materials.

The findings highlight the growing potential of metal–organic cages as catalysts that imitate key features of enzymes, including substrate recognition, selective binding, and control within a confined reaction site. They also expand the scope of asymmetric photocatalysis by showing that a ground-state aromatic compound can participate selectively with an excited alkene under the direction of a chiral molecular container. The researchers’ strategy could inspire further cage-catalyzed photochemical reactions and may ultimately contribute to more efficient methods for producing structurally complex molecules relevant to pharmaceuticals, natural-product synthesis, and advanced chemical technologies.

Subject of Research: Intermolecular asymmetric dearomative photocycloaddition of (benzo)furans with excited alkenes using chiral metal–organic cage catalysts.

Article Title: Intermolecular asymmetric dearomative photocycloaddition of (benzo)furans with excited alkenes via cage-confined catalysis

News Publication Date: 11-Jun-2026

Web References: Chinese Journal of Catalysis article page; DOI: 10.1016/S1872-2067(26)65001-2

References: Chinese Journal of Catalysis, “Intermolecular asymmetric dearomative photocycloaddition of (benzo)furans with excited alkenes via cage-confined catalysis.”

Image Credits: Chinese Journal of Catalysis

Keywords

Photocatalysis, asymmetric synthesis, dearomatization, photocycloaddition, metal–organic cages, enzyme-mimetic catalysis, chiral catalysis, (benzo)furans, excited alkenes, synthetic chemistry

The newly devised strategy hinges on the utilization of chiral phosphoric acid (CPA) catalysts in conjunction with 2-naphthol as a cofactor, which dramatically enhances reactivity and stereochemical outcomes by facilitating the generation of a more reactive and sterically pronounced intermediate known as naphthoquinone methylene (NQM). This intermediate represents a subtle yet crucial modification from traditional QM species that underpins the method’s unprecedented stereoselective control. Beyond enhancing reactivity, the approach elegantly integrates atropselectivity—control over the spatial orientation arising from hindered rotation around a bond—and diastereoselectivity into the macrocyclization paradigm, a significant leap forward in the synthesis of planar chiral architectures.

Planar chiral cyclophanes have long fascinated chemists due to their unique three-dimensional structures conferring distinct conformational rigidity, which has active consequences for molecular recognition, catalytic properties, and interaction efficacy with biological targets. The conformational stability of these macrocycles is paramount, as it modulates their activity and functional potential. Traditionally, chemists have tackled the challenge of conferring such stability through strategies like incorporating bulky groups adjacent to the aromatic core or manipulating the length of the ansa bridge. The present study, however, pushes the frontier by introducing chiral units into the ansa chain, a somewhat underexplored avenue owing to the complexity involved in achieving efficient macrocyclization that selectively generates planar chirality while maintaining precise stereocontrol.

The team’s work systematically unravels how the position and bulk of substituents, particularly at the benzylic site adjacent to the quinone moiety, can dramatically influence the conformational and configurational stability of cyclophanes. Intriguingly, even with an extension of the ansa chain by two carbon atoms—a modification usually detrimental to chiral integrity—the planar chirality remained intact, emphasizing the delicate interplay between macrocycle size and functional group positioning in preserving stereochemical fidelity. This insight provides a valuable framework for understanding how steric factors balance kinetic accessibility with thermodynamic stability in macrocycle formation.

The exploration began with meticulous catalyst screening under dilute conditions, employing toluene and molecular sieves to optimize reaction kinetics and minimize side reactions. CPA catalysts derived from H8-BINOL frameworks bearing bulky 3,3′-substituents emerged as optimal, balancing steric demands with chiral environment rigidity to achieve remarkable yields and enantioselectivities. Solvent and temperature variation studies confirmed that this catalytic system strikes a near-ideal balance, highlighting the delicate electronic and steric orchestration required for such complex macrocyclizations.

Further exploration of substrate scope demonstrated the reaction’s remarkable tolerance to a diverse array of substituent patterns on the naphthalene ring. Electron-donating and electron-withdrawing groups, including methyl, bromine, and heteroaryl substituents, were well-accommodated, allowing for the synthesis of a broad spectrum of planar chiral cyclophanes. Modifications at the C2 hydroxyl substituent from methyl to various benzyl derivatives further extended the toolbox for functional group diversity, achieving high stereochemical outcomes across this spectrum. Ansa chain variability was also probed, with chain lengths from 12 to 17 atoms affording desired macrocycles in suitable yields and stereoselectivities. However, extending to an 18-atom chain significantly reduced diastereoselectivity, likely due to increased conformational flexibility leading to planar chirality epimerization—a vital consideration for future molecular designs.

Mechanistic insights were garnered through a combination of control reactions and kinetic studies which corroborated a nucleophilic attack on the NQM intermediate via an intramolecular pathway rather than an SN2-type displacement. The free naphthol hydroxyl moiety was found to be indispensable, mediating not only intermediate formation but also imparting essential stereochemical bias through hydrogen bonding and steric interactions within the chiral catalyst’s pocket. These findings underscore the ingenuity of leveraging subtle auxiliary groups to fine-tune reaction pathways and selectivities—a hallmark of modern asymmetric catalysis.

Delving deeper, the research outlined a sophisticated stereochemical model assigning the configuration outcomes based on steric shielding by the chiral phosphoric acid catalyst framework. This model rationalizes the simultaneous control of central (carbon-based) and planar (aromatic ring) chirality, an intricate feat rarely achieved in macrocyclic chemistry. Such dual stereocontrol opens avenues for crafting molecules with highly defined three-dimensional shapes and predictable chiral environments, crucial for downstream applications.

The synthetic utility of the resultant planar chiral cyclophanes was elegantly demonstrated through versatile functionalization reactions. The team successfully grafted various functional groups onto the cyclophane scaffold, including propargyl moieties and indomethacin-derived ester conjugates, showcasing the platform’s potential to generate complex bioactive analogs. Notably, the cyclophane framework was adapted to assemble a bifunctional thiourea catalyst, which manifested moderate to good enantioselectivity in Michael addition reactions, signifying a breakthrough in the design of new chiral catalysts derived from macrocyclic precursors.

This work represents a milestone in asymmetric catalysis and macrocycle synthesis, illuminating new mechanistic principles and synthetic methodologies. By integrating chiral phosphoric acid catalysis, innovative intermediate stabilization via 2-naphthol cofactors, and judicious substrate design, the researchers have unlocked pathways to structurally complex and stereochemically rich planar chiral cyclophanes. These findings not only deepen our comprehension of chirality’s structural underpinnings in macrocycles but also hint at the far-reaching potential of these compounds across chemical biology, materials science, and asymmetric catalysis.

In conclusion, the organocatalytic enantio-, atropo-, and diastereoselective macrocyclization of quinone methides pioneered by Zhao and colleagues sets a new precedent in chemical synthesis. It bridges gaps between fundamental understanding and practical application, promising to inspire a generation of research into conformationally stable planar chiral frameworks. Their insightful mechanistic studies and scalable synthetic routes could revolutionize how chemists approach the synthesis of sophisticated chiral macrocycles, opening doors to novel pharmaceuticals and catalysts defined by precise three-dimensional character.

This landmark study was published in the Chinese Chemical Society’s flagship journal, CCS Chemistry, reflecting its significance to the broader chemical science community. It embodies a fusion of cutting-edge synthetic methodology, mechanistic elucidation, and applied functionalization that collectively advances the frontier of asymmetric catalysis and macrocyclic chemistry.

Subject of Research: Not applicable
Article Title: Organocatalytic Enantio-, Atrop-, and Diastereoselective Macrocyclization of Quinone Methides
News Publication Date: 18-Sep-2025
Web References:
https://www.chinesechemsoc.org/journal/ccschem
http://dx.doi.org/10.31635/ccschem.025.202506108
Image Credits: CCS Chemistry

Keywords

Asymmetric catalysis, planar chiral cyclophanes, organocatalysis, macrocyclization, chiral phosphoric acid, naphthoquinone methylene intermediates, atropselectivity, diastereoselectivity, stereoselective synthesis, conformational stability, chemical catalysis, functionalized macrocycles